drugset / Trial / NCT00114127

Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome

NCT00114127

Phase 3 Completed 28 enrolled Massachusetts General Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to examine the safety and efficacy of duloxetine for the treatment of social anxiety disorder.

Timeline

Start
2004-06
Primary completion
2008-11
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Duloxetine Small molecule 60 mg
Comparator Duloxetine Small molecule 120 mg

Indications